Valeant Pharmaceuticals International (NYSE: VRX ) reported earnings on May 2. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Valeant Pharmaceuticals International missed slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share expanded. GAAP loss per share expanded.
Gross margins expanded, operating margins dropped, net margins shrank.
Valeant Pharmaceuticals International logged revenue of $1.07 billion. The 12 analysts polled by S&P Capital IQ looked for revenue of $1.09 billion on the same basis. GAAP reported sales were 25% higher than the prior-year quarter's $856.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.30. The 17 earnings estimates compiled by S&P Capital IQ predicted $1.25 per share. Non-GAAP EPS of $1.30 for Q1 were 14% higher than the prior-year quarter's $1.14 per share. GAAP EPS were -$0.09 for Q1 compared to -$0.04 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 71.9%, 450 basis points better than the prior-year quarter. Operating margin was 16.5%, 420 basis points worse than the prior-year quarter. Net margin was -2.6%, 110 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $1.08 billion. On the bottom line, the average EPS estimate is $1.31.
Next year's average estimate for revenue is $4.59 billion. The average EPS estimate is $5.68.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 200 members out of 227 rating the stock outperform, and 27 members rating it underperform. Among 77 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 70 give Valeant Pharmaceuticals International a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Valeant Pharmaceuticals International is outperform, with an average price target of $77.67.
- Add Valeant Pharmaceuticals International to My Watchlist.